Board of Directors

Board of Directors

  • Dr. James Young PhD
    Chairman, Director and Chief Executive Officer
    Close
    Dr. James Young PhD
    Chairman, Director and Chief Executive Officer
    Close

    Dr. Young currently serves as chairman of the Board of Directors of Novavax, Inc. (NASDAQ: NVAX) and is on the Board of Directors for 3-V Biosciences, Inc., a private drug company. Dr. Young was President of R&D for MedImmune, Inc. from 1989 through 2008 following its $15.6 billion sale to AstraZeneca PLC in 2007. During his tenure, Dr. Young was directly involved in the development of approximately twenty clinical programs and the commercialization of numerous key drugs while managing approximately 1,500 people and controlling an annual budget in excess of $700 million. Prior to his tenure at MedImmune, Dr. Young was a Director in the Department of Molecular Genetics at Smith Kline and French Laboratories, now part of GlaxoSmithKline. Dr. Young has served on the Boards of Directors of Xencor, Inc., Iomai, Inc. and Arriva Pharmaceuticals, Inc. He received his Ph.D. in Microbiology and Immunology from Baylor College of Medicine.

  • Ian Hume PhD
    Director
    Close
    Ian Hume PhD
    Director
    Close

    Mr. Hume was an Independent Director of Carbon Friendly Solutions Inc. from 2010 to 2015. Hume had a long and varied career with the World Bank, which included assignments as both macro- and project economist, multiple managerial positions including Division Chief, Eastern Europe, Deputy Director of the Bank’s Energy Department, and Country Director and Resident Representative in Poland. Since retiring from the Bank in 1994 Hume has operated as an independent consultant and has continued to do high level consulting assignments for the Bank’s senior management and Executive Board. These have included studies of the World Bank’s internal controls, program evaluations relating to Trust Fund management and to combatting fraud and corruption in Bank operations.
    Hume has also been engaged in representing private companies: technical advisor to EUROGAZ Gas Pipeline from 1995 to 1996; in telecommunications (Ameritech, Chicago 1995-6); Grupa ITI (1996-2005), Poland’s largest private media company; and in building materials (Rugby Cement, UK, 2003-5) VP Business Development in Poland; coordinator of a consortium for an LNG Feasibility Study in Poland in 2007; Co-author and team member with ICFI Inc (Fairfax VA), Mozambique Gas Master Plan (2012), under World Bank contract to Mozambique Ministry of Energy.

  • Lawrence Siegel BSc
    Director
    Close
    Lawrence Siegel BSc
    Director
    Close

    Mr. Siegel joined MTI in January of 2014 as a consultant to the Board of Directors. On February 14, 2014, he was named CEO. Mr. Siegel is a seasoned executive with forty years of international experience. A graduate of UCLA, he holds two degrees. He has been President of a large number of high profile companies including: Seeburg (XCOR NASDAQ), Atari (ATI AMERICAN), U.S. Digital Communications (USDI NASDAQ), and Sega Europe (SGAMY NIKKEI) and has held managerial positions or offered consulting services to such well-known companies as: Bally, WMS, Sony, Mattel, SGI, Konami, Taito, Data East, and THQ. Mr. Siegel brings to MTI the hands-on skills necessary to transition the company from a technology start-up to a multinational corporation capable of delivering and sustaining revenues.

Executive Team

EXECUTIVE TEAM

  • Dr. James Young PhD
    CEO and Interim CFO
    Close
    Dr. James Young PhD
    CEO and Interim CFO
    Close

    Dr. Young currently serves as chairman of the Board of Directors of Novavax, Inc. (NASDAQ: NVAX) and is on the Board of Directors for 3-V Biosciences, Inc., a private drug company. Dr. Young was President of R&D for MedImmune, Inc. from 1989 through 2008 following its $15.6 billion sale to AstraZeneca PLC in 2007. During his tenure, Dr. Young was directly involved in the development of approximately twenty clinical programs and the commercialization of numerous key drugs while managing approximately 1,500 people and controlling an annual budget in excess of $700 million. Prior to his tenure at MedImmune, Dr. Young was a Director in the Department of Molecular Genetics at Smith Kline and French Laboratories, now part of GlaxoSmithKline. Dr. Young has served on the Boards of Directors of Xencor, Inc., Iomai, Inc. and Arriva Pharmaceuticals, Inc. He received his Ph.D. in Microbiology and Immunology from Baylor College of Medicine.

Contact Us

Newsletter

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere